BeiGene Bags $750m, Sees China Reforms Creating New Opportunities

A spectacular secondary offering will enable Beijing-based BeiGene to expand in both novel R&D and manufacturing in 2018, driven largely by an integrated China-global approach, its CFO says.

Money Wave

Nothing feels better than starting the New Year with a full arsenal.

BeiGene (Beijing) Co. Ltd. is in such a sweet spot, the Beijing-based company having successfully completed a secondary offering...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer